ArticleJournal of translational medicine2026
Disruption of the NDC80-Nek2 axis suppresses glioblastoma stemness and enhances therapeutic efficacy.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGlioblastoma (GBM), the most aggressive primary brain tumor, demonstrates resistance to standard therapies, primarily due to the presence of GBM stem cells (GSCs), the mechanisms of which remain poorly understood.
methodsTo identify therapeutic targets for GSCs, we utilized multiple datasets to screen for differentially expressed pathways and potential targets. The prognostic and survival characteristics of the potential target NDC80 were analyzed using the TCGA and CGGA datasets. The molecular function of NDC80 was evaluated through western blot, RT-qPCR, limiting dilution assays, sphere-forming assays, cell proliferation, and cell cycle analysis. Orthotopic GBM xenograft models were established to assess the anti-GBM effects of NDC80 inhibition. Co-immunoprecipitation assays were performed to confirm the interaction between NDC80 and Nek2 after treatment with the NDC80 inhibitor TAI-1.
resultsWe performed an integrated analysis of multiple datasets and identified significant differences in cell cycle–related pathways between GSCs and non-GSCs. Among these, NDC80, a core kinetochore protein crucial for accurate chromosome segregation during the G2/M phase of the cell cycle, was found to be markedly overexpressed in GSCs. Analysis of public databases revealed that high NDC80 expression is associated with poor patient prognosis and aggressive clinical features. Functional studies demonstrated that silencing NDC80 suppresses GSC stemness and tumorigenic potential, as evidenced by reduced self-renewal and proliferation in vitro, induction of G2/M phase arrest, and impaired tumor growth in an orthotopic brain tumor xenograft model. Furthermore, we showed that TAI-1, a small-molecule inhibitor that disrupts the NDC80–Nek2 interaction, effectively suppresses GSC proliferation and tumorigenesis, leading to a significant extension of survival in mice bearing orthotopic GBM tumors.
conclusionsOur findings highlight NDC80 as a key regulator of GBM pathogenesis and a promising prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.